GJL
AVXL icon

Gendell Jeffrey L’s Anavex Life Sciences AVXL Stock Holding History

Gendell Jeffrey L’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-19,971
Closed -$63K – 50
2020
Q1 		$63K Buy
+19,971
New +$69.6K 0.02% 53

Other funds holding AVXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Gendell Jeffrey L's AVXL Position: Q2 2020 in Review

Gendell Jeffrey L sold out of Anavex Life Sciences (AVXL) in Q2 2020, closing a stake of 19,971 shares — an estimated $63K sold.

Gendell Jeffrey L first reported a position in AVXL in Q1 2020 and held it in 1 quarter. The position peaked at $63K in Q1 2020. 77 funds tracked by Wall St. Rank hold AVXL as of Q2 2020.

  • Gendell Jeffrey L reported no remaining Anavex Life Sciences position as of Q2 2020 after selling out during the quarter.
  • Gendell Jeffrey L sold 19,971 Anavex Life Sciences shares in Q2 2020, an estimated $63K.
  • Gendell Jeffrey L first reported a position in Anavex Life Sciences in Q1 2020 and held it in 1 quarter.
  • Gendell Jeffrey L's Anavex Life Sciences position peaked at $63K in Q1 2020.
  • 77 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2020.

Based on Gendell Jeffrey L's 13F filing for Q2 2020, filed 13 Aug 2020.